申请人:Schering Aktiengesellschaft
公开号:US04564610A1
公开(公告)日:1986-01-14
Substituted 5H-pyrimido[5,4-b]indoles of Formula I ##STR1## wherein R.sup.2 is halogen; the oxadiazolyl group ##STR2## wherein R" is lower alkyl with up to 3 carbon atoms; C.sub.1-5 -alkyl, cycloalkyl, aralkyl, or aryl; OR.sup.I, SO.sub.n R.sup.I with n being 0, 1, or 2, or ##STR3## wherein R.sup.I is hydrogen, C.sub.1-5 -alkyl, cycloalkyl, aralkyl, or aryl; ##STR4## wherein R.sup.II and R.sup.III are hydrogen, C.sub.1-5 -alkyl, C.sub.3-5 -alkenyl, cycloalkyl, aralkyl, aryl, or, with the connecting N-atom, a 5- or 6-membered heterocyclic ring; and R.sup.A is hydrogen; the oxadiazolyl group ##STR5## wherein R" is lower alkyl with up to 3 carbon atoms; halogen, nitro, OR.sup.I, SO.sub.n R.sup.I with n being 0, 1, or 2, ##STR6## wherein R.sup.I is hydrogen, C.sub.1-5 -alkyl, cycloalkyl, aralkyl, or aryl; ##STR7## wherein R.sup.II and R.sup.III are hydrogen, C.sub.1-5 -alkyl, cycloalkyl, C.sub.3-5 -alkenyl, aralkyl, aryl, or, with the connecting N-atom, a 5- or 6-membered heterocyclic ring; or PO(OR).sub.2 wherein R is C.sub.1-5 -alkyl, exhibit strong affinity for binding to benzodiazepine receptors. The novel compounds are suitable for use in psychopharmaceutical preparations.
化学式为I的5H-嘧啶并[5,4-b]吲哚,其中R.sup.2为卤素; 氧代二唑基团##STR2##其中R"为具有最多3个碳原子的低级烷基; C.sub.1-5-烷基,环烷基,芳基烷基或芳基; OR.sup.I,SO.sub.nR.sup.I,其中n为0,1或2,或##STR3##其中R.sup.I为氢,C.sub.1-5-烷基,环烷基,芳基烷基或芳基; ##STR4##其中R.sup.II和R.sup.III为氢,C.sub.1-5-烷基,C.sub.3-5-烯基,环烷基,芳基烷基,芳基或与连接的N原子,为5或6成员杂环环; 而R.sup.A为氢; 氧代二唑基团##STR5##其中R"为具有最多3个碳原子的低级烷基; 卤素,硝基,OR.sup.I,SO.sub.nR.sup.I,其中n为0,1或2,##STR6##其中R.sup.I为氢,C.sub.1-5-烷基,环烷基,芳基烷基或芳基; ##STR7##其中R.sup.II和R.sup.III为氢,C.sub.1-5-烷基,环烷基,C.sub.3-5-烯基,芳基烷基,芳基或与连接的N原子,为5或6成员杂环环; 或PO(OR).sub.2,其中R为C.sub.1-5-烷基,具有与苯二氮平受体结合的强亲和力。这些新化合物适用于精神药物制剂的使用。